

ASX Announcement

Medibio Limited – 13 OCTOBER 2017



Medibio completes heavily oversubscribed institutional placement for \$13.9 million to accelerate commercialisation

Highlights:

- Placement completed, with oversubscriptions accepted up to \$13.9 Million
- Fidelity Investments follows on to maintain 10.6% ownership of the Company
- IFM Investors and Regal FM to become substantial shareholders post-transaction
- Medibio now fully funded to pursue aggressive commercialisation and IP strategy

Sydney, Australia and Minneapolis, MN – 13 October 2017

Medibio Limited (ASX: MEB)(OTCQB: MDBIF) is pleased to announce that it has received firm commitments to raise \$13.9 million via the placement of 38,736,640 ordinary shares at a price of \$0.36 per share. The placement will be conducted in a single tranche using the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A.

The funds will allow the Company to:

- Build out organisational infrastructure for product commercialisation
- Establish requirements and testing of products and products under development for future market verticals
- Development of technology platform and infrastructure, including engineering capability, to support commercialisation
- Position Medibio for regulatory approvals on future products

Aesir Capital Pty Ltd acted as Sole Lead Manager to the transaction.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcm Markets.com and www.asx.com.au.

Additional disclosure required by listing rule 3.10.5A

In accordance with listing rule 3.10.5A in relation to shares issued under the Company's 7.1A capacity details of the placement are:

Effect of raising

The effect of the announced raising on the capital structure of the Company is set out below.

	Number	Dilution
Shares currently on issue	156,196,558	
Placement		
Shares to be issued under LR7.1 placement capacity	23,141,984	14.82%
Shares to be issued under LR7.1A placement capacity	15,594,656	9.98%
Total Shares on issue after completion of the Placement	194,933,198	24.80%

The Company believes the benefits from funds raised in this placement at a discount to the 15-day VWAP of 11.9% outweigh the inability of shareholders to participate. The placement was not underwritten and direct costs of the raising are up to 7.5% of funds raised.

Further Information: Website: www.medibio.com.au	
Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: +1 (952) 465 4787	Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231